Vaxigriptetra

Vaxigriptetra is a quadrivalent influenza vaccine designed to protect against four influenza virus strains, including B/Phuket/3073/2013-like and B/Michigan/01/2021-like viruses. This seasonal flu vaccine helps reduce the risk of influenza infection and its complications. Suitable for adults and children, it is administered annually to match circulating flu strains.

Vaxigriptetra is used to provide active immunization against influenza caused by specific virus strains. It is indicated for individuals aged six months and older to help prevent seasonal flu. The vaccine works by stimulating the immune system to produce antibodies against the included viral strains. Annual vaccination is recommended due to the evolving nature of influenza viruses.

After administration, Vaxigriptetra prompts the body to develop immunity against the targeted influenza strains. Common effects include mild soreness at the injection site, low-grade fever, or fatigue, which typically resolve within a few days. Some individuals may experience mild headache or muscle aches as the immune response activates.

Vaxigriptetra should be stored and handled according to manufacturer guidelines to maintain potency. Individuals with a known allergy to any component of the vaccine, including eggs, should avoid its use. Healthcare providers should be informed of any current illnesses or immune conditions before administration. Post-vaccination observation for at least 15 minutes is recommended to monitor for adverse reactions.

Vaxigriptetra may interact with immunosuppressive therapies, potentially reducing the vaccine's effectiveness. Concurrent use with other vaccines should be evaluated by a healthcare provider to avoid overlapping side effects. Blood thinners or medications affecting the immune system may require adjustment or monitoring. Always disclose all medications and conditions to the administering healthcare professional.